Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Posaconazole Oral Suspension Articles

Breakthrough status for Pfizer's palbociclib; Merck & Co Noxafil NDA accepted

11 April 2013

FDA approves Merck' & Co’s Dulera for asthma in patients; firm initiates Ph II trial of Chagas drug candidate

25 June 2010

US IDSA's IFI guidelines recommend S-P's Noxafil

11 February 2008

NCCN advocates Noxafil for IFI in cancer patients

26 March 2007

S-P unveils landmark Noxafil data

29 January 2007

S-P's Noxafil cleared by European Commission

20 November 2006

US FDA clears S-P's Noxafil for expanded indication

30 October 2006

S-P's antifungal Noxafil gets FDA OK

25 September 2006

Review of Congress of European Clinical Microbiology and Infectious Diseases

12 June 2006

Early development of six pharma agents urged in Japan

8 May 2006

Prophylaxis or treatment in coping with invasive fungal infections; EBMT meeting

1 May 2006

US FDA grants priority review to Schering-Plough's Noxafil

27 February 2006

S-P launches Noxafil in the UK for refractory IFI

13 February 2006

S-P's new antibiotic performs well in trials

19 December 2005

EMEA OKs Schering-Plough's Noxafil

8 August 2005

S-P's posaconazole NDA accepted for FDA review

19 July 2004

Positive Ph III data for Schering-Plough's Noxafil

4 August 2003

Showing 1-17 of 17 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS